Alterations in TP53 have been identified in as many as 90% of patients with low hypodiploid ALL, with approximately 50% of these cases having germline TP53 alterations [37], which are associated with inferior event-free survival and overall survival as well as an increased risk of developing secondary cancer [38], regardless of ploidy status. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.